Teriparatide biosimilar - Virchow Group

Drug Profile

Teriparatide biosimilar - Virchow Group

Alternative Names: Bonista; Osteotide

Latest Information Update: 10 Jun 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Virchow Group
  • Class Osteoporosis therapies; Peptide hormones; Skin disorder therapies
  • Mechanism of Action Osteogenesis stimulants; Parathyroid hormone receptor type 1 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Osteoporosis

Most Recent Events

  • 20 May 2015 Virchow Group signed a memorandum of understanding with Sun Pharmaceutical Industries to market its indigenously developed recombinant therapeutic protein for the treatment of Osteoporosis before May 2015 (Virchow Group website, May 2015)
  • 25 Mar 2015 Sun Pharmaceutical Industries has merged with Ranbaxy forming Sun Pharma
  • 21 Oct 2013 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top